REGENXBIO Inc.
For the period ended Dec 31, 2025. Filed Mar 5, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 5, 2026
RGNX$7.69-4.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
(in thousands)
| Accumulated | ||||||
|---|---|---|---|---|---|---|
| Additional · Other · Total | ||||||
| Common Stock · Paid-in · Comprehensive · Accumulated · Stockholders’ | ||||||
| Shares | Amount | Capital | Loss | Deficit | Equity | |
| Balances at December 31, 2023 | 44,046 | $4 | $1,021,214 | $(4,429) | $(705,047) | $311,742 |
| Vesting of restricted stock units, net of tax | 345 | — | (910) | — | — | (910) |
| Exercise of stock options, net of tax | 291 | — | 1,512 | — | — | 1,512 |
| Issuance of common stock under employee stock purchase plan | 105 | — | 1,191 | — | — | 1,191 |
| Issuance of common stock and pre-funded warrants upon public offering, net of transaction costs of $534 | 4,565 | 1 | 131,066 | — | — | 131,067 |
| Exercise of pre-funded warrants | 197 | — | — | — | — | — |
| Stock-based compensation expense | — | — | 38,463 | — | — | 38,463 |
| Unrealized gain on available-for-sale securities, net | — | — | — | 3,688 | — | 3,688 |
| Net loss | — | — | — | — | (227,102) | (227,102) |
| Balances at December 31, 2024 | 49,549 | 5 | 1,192,536 | (741) | (932,149) | 259,651 |
| Vesting of restricted stock units, net of tax | 662 | — | (633) | — | — | (633) |
| Exercise of stock options, net of tax | 68 | — | 318 | — | — | 318 |
| Issuance of common stock under employee stock purchase plan | 158 | — | 1,048 | — | — | 1,048 |
| Issuance of warrants, net of transaction costs | — | — | 1,610 | — | — | 1,610 |
| Exercise of pre-funded warrants | 455 | — | — | — | — | — |
| Stock-based compensation expense | — | — | 34,563 | — | — | 34,563 |
| Unrealized gain on available-for-sale securities, net | — | — | — | 54 | — | 54 |
| Net loss | — | — | — | — | (193,878) | (193,878) |
| Balances at December 31, 2025 | 50,892 | $5 | $1,229,442 | $(687) | $(1,126,027) | $102,733 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.